Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven Santiago

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
Nanoscale Research Letters|November 25, 2011
One-dimensional silver nanostructures on single-wall carbon nanotubesEunice Mercado, Steven Santiago, Luis Baez, et al.
AIDS Research and Therapy|September 27, 2025
Clinical outcomes on B/F/TAF and dolutegravir-based regimens at 12 months following regimen switch: an observational cohort studyPaul E Sax, Janna Radtchenko, Megan Dunbar, et al.
The Journal of Infectious Diseases|May 8, 2012
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)Ann Duerr, Yunda Huang, Susan Buchbinder, et al.
AIDS (London, England)|March 7, 2025
Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruptionGraeme Moyle, Joshua Gruber, Megan Dunbar, et al.
Antiviral Therapy|August 6, 2011
Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patientsJoseph Gathe, Jaime Andrade-Villanueva, Steven Santiago, et al.
AIDS Patient Care and Stds|June 5, 2026
People with HIV Continuing on Complex Regimens in the Era of Treatment Optimization: Characteristics and OutcomesPaul E Sax, Keith J Dunn, Janna Radtchenko, et al.
Plos One|February 14, 2020
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCVSonia Vibhakar Patel, Dushyantha T Jayaweera, Keri N Althoff, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 25, 2008
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adultsFrances H Priddy, Deborah Brown, James Kublin, et al.
Science (New York, N.Y.)|November 6, 2010
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation, Florencia Pereyra, Xiaoming Jia, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
Nanoscale Research Letters|November 25, 2011
One-dimensional silver nanostructures on single-wall carbon nanotubesEunice Mercado, Steven Santiago, Luis Baez, et al.
AIDS Research and Therapy|September 27, 2025
Clinical outcomes on B/F/TAF and dolutegravir-based regimens at 12 months following regimen switch: an observational cohort studyPaul E Sax, Janna Radtchenko, Megan Dunbar, et al.
The Journal of Infectious Diseases|May 8, 2012
Extended follow-up confirms early vaccine-enhanced risk of HIV acquisition and demonstrates waning effect over time among participants in a randomized trial of recombinant adenovirus HIV vaccine (Step Study)Ann Duerr, Yunda Huang, Susan Buchbinder, et al.
AIDS (London, England)|March 7, 2025
Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruptionGraeme Moyle, Joshua Gruber, Megan Dunbar, et al.
Antiviral Therapy|August 6, 2011
Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naive HIV-1-infected patientsJoseph Gathe, Jaime Andrade-Villanueva, Steven Santiago, et al.
AIDS Patient Care and Stds|June 5, 2026
People with HIV Continuing on Complex Regimens in the Era of Treatment Optimization: Characteristics and OutcomesPaul E Sax, Keith J Dunn, Janna Radtchenko, et al.
Plos One|February 14, 2020
Real-world efficacy of direct acting antiviral therapies in patients with HIV/HCVSonia Vibhakar Patel, Dushyantha T Jayaweera, Keri N Althoff, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|April 25, 2008
Safety and immunogenicity of a replication-incompetent adenovirus type 5 HIV-1 clade B gag/pol/nef vaccine in healthy adultsFrances H Priddy, Deborah Brown, James Kublin, et al.
Science (New York, N.Y.)|November 6, 2010
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation, Florencia Pereyra, Xiaoming Jia, et al.
Pageof 1